When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SGEN - Seattle Genetics/Astellas Pharma's PADCEV shows survival benefit in previously treated urothelial cancer
Seagen Inc.
Astellas Pharma (OTCPK:ALPMF) and Seattle Genetics (NASDAQ:SGEN) have announced that a Phase 3 (EV-301) trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall survival (OS) compared to chemotherapy, in locally advanced/metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.
More news on: Astellas Pharma Inc., Seattle Genetics, Inc., Healthcare stocks news,